文献速递临床试验与 GCP基础与转化研究组学、生物样本库与精准医学

黄腐酚微生物组与特征研究(XMaS试验):一项I期三盲安慰剂对照临床试验

Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial.
PubMed 文献 · Trials · 2020-10-07

XMaS试验是一项I期三盲、随机、安慰剂对照临床试验,在健康成人中评估黄腐酚(hops来源黄酮类)的安全性与耐受性。受试者随机接受24 mg/天黄腐酚或安慰剂8周,每2周监测血细胞计数、肝肾功能、电解质及自报健康相关生活质量,并全程询问不良事件。次要目的包括监测炎症、肠道通透性、胆汁酸代谢相关生物标志物及黄腐酚代谢产物,并评估对肠道微生物组成的影响。

要点

  • 黄腐酚24 mg/天或安慰剂干预8周,主要评价健康成人安全性与主观耐受性。
  • 每2周监测血细胞计数、肝肾功能、电解质及自报生活质量,全程记录不良事件。
  • 同步检测血、尿、粪中黄腐酚代谢产物及炎症、肠道通透性、胆汁酸相关标志物。

核心结论

  • 该I期试验将评估黄腐酚在健康成人中的安全性与耐受性,并为未来慢性病II期试验提供比较数据。

研究设计与样本

  • 三盲、随机、安慰剂对照I期临床试验,受试者为健康成人,随机接受24 mg/天黄腐酚或安慰剂8周。

关键数值与推荐

  • 干预剂量为24 mg/天黄腐酚或安慰剂,持续8周。
  • 每2周采集血细胞计数、肝肾功能、电解质及自报健康相关生活质量指标。

临床怎么用

  • 为黄腐酚作为膳食补充剂或医疗食品成分的临床安全性与耐受性提供I期证据。
  • 为后续在慢性病中开展II期试验提供生物标志物与比较数据基础。

局限性

  • 原文未报告本试验的实际结果数据,仅描述设计。
  • 研究对象为健康成人,结论外推至慢性病人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Natural products may provide a source for the discovery and development of adjunctive pharmacological interventions to modulate the inflammatory pathways contributing to chronic disease. Xanthohumol, a flavonoid from the hops plant (Humulus lupulus), has antioxidant and anti-inflammatory properties and may act as a prebiotic to the intestinal microbiota. Xanthohumol is not currently approved as a drug by the US Food and Drug Administration (FDA), but is available as a dietary supplement and ingredient in medical foods. To formally test the safety of xanthohumol, a phase I clinical trial ("XMaS") was designed and approved under an Investigational New Drug application to the US FDA. The main objective is to examine the clinical safety and subjective tolerability of xanthohumol in healthy adults compared to placebo. Additional aims are to monitor biomarkers related to inflammation, gut permeability, bile acid metabolism, routes, and in vivo products of xanthohumol metabolism, and to evaluate xanthohumol's impact on gut microbial composition. METHODS: The safety and tolerability of xanthohumol in healthy adults will be evaluated in a triple-masked, randomized, placebo-controlled trial. Participants will be randomized to either 24 mg/day of xanthohumol or placebo for 8 weeks. Blood cell counts, hepatic and renal function tests, electrolytes, and self-reported health-related quality of life measures will be collected every 2 weeks. Participants will be queried for adverse events throughout the trial. Xanthohumol metabolites in blood, urine, and stool will be measured. Biomarkers to be evaluated include plasma tumor necrosis factor-alpha, various interleukins, soluble CD14, lipopolysaccharide-binding protein, fecal calprotectin, and bile acids to assess impact on inflammatory and gut permeability-related mechanisms in vivo. Stool samples will be analyzed to determine effects on the gut microbiome. DISCUSSION: This phase I clinical trial of xanthohumol will assess safety and tolerability in healthy adults, collect extensive biomarker data for assessment of potential mechanism(s), and provide comparison data necessary for future phase II trials in chronic disease(s). The design and robustness of the planned safety and mechanistic evaluations planned provide a model for drug discovery pursuits from natural products. TRIAL REGISTRATION: ClinicalTrials.gov NCT03735420 . Registered on November 8, 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bradley R, Langley BO, Ryan JJ, et al. Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial. Trials. 2020. PMID: 33028396. doi:10.1186/s13063-020-04769-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。